By Frank Prenesti
Date: Friday 07 Aug 2026
(Sharecast News) - Shares in Oxford Biomedica tanked by a quarter on Friday after the cell and gene therapy manufacturer slashed its full year revenue and margins forecast citing short‑term client ordering delays, programme deferrals and operational delays at its North Carolina facility.
| Total Voting Rights | 02-Jan-2026 | 07:00 | RNS |
| Block Listing Return | 02-Jan-2026 | 07:00 | RNS |
| Should you buy shares in Oxford Biomedica? | 29-Jul-2026 | Times |
| Need to know: Opec cuts forecast ... Tesco cuts ... | 16-Aug-2008 | Times |
| Need to know | 10-May-2008 | Times |
| DSG International may be losing its spark | 12-Feb-2008 | Telegraph |
| Oxford BioMedica clinches $690m licensing deal f... | 29-Mar-2007 | The Independent |
No recent information was found.
| Currency | UK Pounds |
| Share Price | 487.00p |
| Change Today | -0.50p |
| % Change | -0.10 % |
| 52 Week High | 913.00 |
| 52 Week Low | 439.50 |
| Volume | 407,393 |
| Shares Issued | 121.04m |
| Market Cap | £589.49m |
| Beta | 0.03 |
| RiskGrade | 125 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 17:07 | 10,000 @ 487.00p |
| 16:35 | 99,951 @ 487.00p |
| 16:35 | 179 @ 487.00p |
| 16:35 | 6 @ 487.00p |
| 16:35 | 185 @ 487.00p |
| Chair | Roch Doliveux |
| CEO | Frank Mathias |
| CFO | Lucinda (Lucy) Crabtree |
You are here: research